Home › Prostate Cancer › NCT05295407

Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy

Observational and Prospective Study on the Performance of Inherited Risk Assessment for Predicting Prostate Cancer From Prostate Biopsy (GenBx)

Who can join

Ages 40 to 69 · Men

Inclusion Criteria:

* Consecutive patients undergoing prostate biopsy for detection of prostate cancer
* Aged 40 to 69 years
* Four ethnicity groups (Caucasian, African Americans, East Asians, Latinos)
* PSA between 2.5-10 ng/mL

Exclusion Criteria:

* Previous diagnosis of prostate cancer.
* Ethnicity outside the inclusion criterion (including mixed ethnicity).
* Any prior PSA test result outside the range of inclusion criterion.

About the study

Condition: Prostate cancer Intervention: Biopsy and inherited risk assessment

What is being tested

• Genetic Assessment (genetic)

Sponsor: Endeavor Health · Participants: 1,000 · Started: Dec 13, 2021

Contact the study team

• Annie Ashworth · Phone: 2243647502

Official record on ClinicalTrials.gov — NCT05295407

Locations in the U.S.

Conditions

• Prostate Cancer

From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.